Jump to Navigation
Trends and Sentiments
Comments and Analysis
The Wall Street Journal: Swiss banks offering U.S....
Here's How Wonder Woman Will Look In 'Batman V...
Tribune Publishing looking for acquisitions
This Traffic Backup Brought To You By ...
Fast food workers vow civil disobedience
Here Are The Countries That Smoke The Most Marijuana
Nibali closes in on Tour de France title
SWAT plane arrest: Father speaks out
Banks now expect smaller fines under US tax deal
Goldman mortgage deal could reach $1.25B
BioSante CEO Pleased With LibiGel Progress
Biotech Deal Activity Takes a Breather
Biotech Deals Keep Flowing, From Big Pharma to Industrials
Six Trades on FDA, Clinical Trial Binary Events
Biosante: Key Catalysts Should Renew Investor Interest
15 Biotech Stocks With the Lowest Put/Call Ratios
Amgen, Celgene and Novartis in the Fight Against Pancreatic Cancer
Is BioSante Pharmaceuticals Next in Line to Receive Institutional Praise?
BioSante Attracts Institutional Investors Ahead of Key FDA Catalysts in 2011
Life Sciences Companies Raise Record Amounts of Capital
Two Biotechs Poised for Gains as Call Options Boost Investor Sentiment
Two Small-Cap Biotechs and a Sector ETF to Keep You Afloat During the Market Correction
Top 24 Small Cap Stocks Being Chased by Smart Money
Biosante Pharma Up After FDA Announces Review of Testosterone Gel
Why BioSante Expects a Positive Review of Drug for Female Sexual Disorder
Platform and Specialty Pharmaceutical Companies Could Strengthen in Face of Big Pharma's Patent Cliff
7 Speculative Healthcare Stocks to Rejuvenate Your Portfolio
6 Prime Biotechs for Short and Long-Term Gains
7 Dirt-Cheap Takeover Targets in Biotech
With Cancer Vaccines in Play, Will Investors Continue to Buy-In?
3 Small Cap Biotech Companies With Future Potential
3 Micro Caps With 50% Upside Potential
Upcoming PDUFA Dates for Sub-$5 Stocks
Friday Options Brief: ADM, TRW, RDWR & BPAX
Here's How Wonder Woman Will Look In '...
HOUSE OF THE DAY: Steel Tycoon Sells Gigantic...
EUR/GBP: 1.264 USD/EUR: 1.3431 JPY/USD: 101.84
Bullfax.com - Market News & Analysis 2008-2011
Terms & Conditions